2026 Prevention of Seasonal COVID-19, Influenza, and RSV Infections

To support evidence-based clinical & shared decision-making during the 2026-2027 respiratory tract infection season, IDSA developed rapid guidelines for the use of U.S-licensed vaccine against COVID-19, Influenza, and RSV in adult and pediatric patients who are immunocompromised.    Immunocompromised patients are defined as individuals who have impaired immune systems either due to their underlying disease (e.g. HIV, malignancy) or due to the medications they must take (e.g. solid organ transplant). Patients with chronic organ dysfunction (e.g. end stage renal disease: requiring dialysis, cirrhosis, or end-stage heart disease) are not considered in this guideline.   These recommendations address patients who have a hematologic malignancy, primary immunodeficiency, autoimmune disease treated with immunosuppressants or biologics, or HIV with severe immunosuppression (CD4 <15% or <200/mm³), as well as patients who are recipients of solid organ transplants (SOT), hematopoietic cell transplantation (HCT), chimeric antigen receptor T-cell therapy (CAR-T), or solid-tumor chemotherapy.